Eiger BioPharmaceuticals, Inc. (EIGR) announced a presentation of positive phase 2 study results of Avexitide in congenital hyperinsulinism. Avexitide infusion demonstrated significant reductions in glucose infusion requirements to maintain euglycemia or normal glucose levels in neonates and infants. Avexitide represents a promising, targeted approach for the treatment of congenital hyperinsulinism.
Avexitide is a targeted, first-in-class, GLP-1 antagonist in development for the treatment of hyperinsulinism, an ultra-rare, life-threatening, pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children.
Avexitide 100, 200 and 1,000 pmol/kg/min ascending doses demonstrated 1.3 (15%), 2.9 (24%), and 4.3 (56%) mg/kg/min reductions in glucose infusion rate relative to placebo, respectively, and entirely abolished the glucose requirement in 50% of patients at the top dose.
Avexitide was well-tolerated in this study. Adverse events were typically mild in severity and transient, and there were no serious adverse events.
For comments and feedback contact: editorial@rttnews.com
Business News